Quick Verdict
WHOOP just made two moves that matter beyond its own ecosystem. On August 18 it opened Advanced Labs, its clinician-reviewed blood testing program, to everyone: no WHOOP band, no membership, panels starting around $150, with draws at roughly 2,000 Quest Diagnostics locations. And it added Galleri, GRAIL's multi-cancer early detection blood test, for $799 a year, delivered with results and follow-up inside the WHOOP app.
The catch is not the price. It is the numbers behind the screening. Galleri is a real, studied test with genuine strengths, especially for aggressive cancers that have no other screening at all. A negative result cannot rule out cancer, positive signals require follow-up, and the figures below need to be interpreted with their study definitions. Whether it belongs in your health apps and devices depends on your age, your risk, and how you will handle an ambiguous result. Use the study information below as a starting point for a discussion with a qualified clinician.
What WHOOP Announced
Two changes landed together. First, Advanced Labs no longer requires a WHOOP membership or a wearable. Anyone can book a blood draw through the WHOOP app, get panels covering cardiovascular, metabolic, hormonal, and inflammatory markers from about $150, and receive clinician-reviewed results with recommendations. Licensed providers order the tests and review the reports.
Second, the lineup now includes Galleri, GRAIL's blood test that screens for a cancer signal across more than 50 cancer types from a single draw, and predicts where in the body a detected signal likely originated. Through WHOOP it costs $799 as a once-a-year test, below the roughly $949 GRAIL has charged directly. It is intended for adults 50 and older, and is not for people under 22, currently pregnant, or in active cancer treatment.
Strategically, this is WHOOP finishing a pivot it started when it launched Advanced Labs with Quest in 2025: from a recovery band for athletes into a general health platform where the wearable is optional and the lab work is the product. A cancer screen in the same app as your sleep and strain data is the clearest statement yet of that ambition.
What Galleri Actually Is
Galleri looks for fragments of DNA that tumors shed into the bloodstream, and uses the chemical patterns on those fragments to flag a possible cancer signal and estimate its origin. It is a screening test, not a diagnosis: a positive result means follow-up imaging and workup with a clinician, and a negative result does not rule cancer out.
Its appeal is real. Standard screening exists for only a handful of cancers, and many of the deadliest, including pancreatic and ovarian, are usually found late precisely because nothing screens for them. A blood test that can sometimes surface those cancers earlier is a legitimately new capability, and that is why it has drawn both serious research and serious hype.
The Numbers the Marketing Does Not Lead With
GRAIL's May 31, 2026 manufacturer report describes the full 35,878-participant PATHFINDER 2 cohort. It reports:
| Measure | Result in that report |
|---|---|
| Overall episode sensitivity | 39.3% |
| Sensitivity for the specified high-mortality cancer group | 69.8% |
| Positive predictive value | 60.3% |
| Specificity | 99.6% |
Episode sensitivity concerns cancers confirmed in the study's follow-up window; it is not a universal stage-I detection rate. These measures answer different questions and should not be combined with values from an earlier analysis or a different study. The report is manufacturer-authored, and these figures do not establish a reduction in cancer mortality.
A negative result does not rule cancer out, and a positive result needs clinical follow-up. The test does not replace recommended screening. Regulatory status and eligibility should be checked with the current provider and the clinician ordering the test rather than inferred from a past announcement.
Discuss screening with a clinician
Ask what the test can and cannot detect, which standard screenings you should continue, what follow-up a positive result would involve, and what costs or risks that follow-up could bring. Eligibility for purchase does not establish that a test is appropriate for you.
What It Means for the Wearable Wars
Advanced Labs without a membership is arguably the bigger business story. WHOOP spent a decade as the strictest subscription company in wearables, and it just built a front door that requires no subscription and no hardware. Oura added telehealth and health-record imports with Ring 5; Function Health raised $450M on lab testing; now WHOOP sells lab work to people who have never worn a WHOOP. Every serious player is converging on the same thesis: the money and the moat are in owning your health data pipeline, not the gadget.
If you are evaluating WHOOP itself, our guides to whether WHOOP is still worth it in 2026 and WHOOP 5 vs WHOOP MG cover the wearable side, and the best no-subscription alternatives covers the exits.
Where Beacon Fits
Beacon sits on the same conviction with a different architecture: your labs belong next to your daily behavior, not in a separate app per vendor. Beacon does not read lab results, so a Galleri result stays with your clinician. What Beacon does track is the sleep, training, nutrition and recovery data it reads from whatever you wear, which is the context a screening result gets interpreted against.
A screening like Galleri, if you choose it, produces exactly the kind of result that should be kept with your other medical records: it is context that belongs with your history, your other labs, and your clinician. Whoever you buy your blood work from, keep your copies, and keep them somewhere that outlives any one company's app. That principle, not any single test, is what proactive health actually runs on.
FAQ
How much does the Galleri test cost through WHOOP?
$799 as a once-a-year test through WHOOP Advanced Labs, below the roughly $949 GRAIL has charged directly. Blood draws happen at about 2,000 Quest Diagnostics locations in the US, and no WHOOP membership or wearable is required.
Do I need a WHOOP membership to use Advanced Labs?
No. As of August 18, 2026, WHOOP Advanced Labs is open to everyone, with panels starting around $150. You book through the WHOOP app, and licensed clinicians order the tests and review results.
How accurate is the Galleri cancer test?
The full-cohort PATHFINDER 2 figures above come from GRAIL's May 31, 2026 report. Sensitivity, specificity and positive predictive value describe different aspects of performance; none establishes that an individual is cancer-free or that screening improves survival.
Does a negative Galleri result mean I do not have cancer?
No. Galleri misses most early-stage cancers, so a negative result is weak reassurance. It is designed to add coverage for cancers that have no standard screening, not to replace colonoscopies, mammograms, or any recommended screening you already do.
Is Galleri FDA approved?
GRAIL's May 31, 2026 report states that the test had not received FDA clearance or approval. Check the provider's current labeling and regulatory information with the clinician ordering it.
Who is eligible for Galleri through WHOOP?
It is intended for adults 50 and older, particularly those at elevated cancer risk. It is not available to people under 22, and is not intended for anyone who is pregnant or currently undergoing cancer treatment.